Immuno-Biological Lab, Apr-Jun (1Q) Ordinary Profit Increases by 2%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Aug 8, 2025 3:30 pm JST Earnings

4570 Immuno-Biological Laboratories Co., Ltd. 【J-GAAP】

Earnings Report

Immuno-Biological Laboratories Co., Ltd. <4570> [TSE Growth] announced its financial results after the market closed on August 8th (15:30). The consolidated ordinary profit for the first quarter of the fiscal year ending March 2026 (April to June) was 57 million yen, a 1.8% increase compared to the same period last year. However, Progress toward the full-year plan of 240 million yen was 23.8%, almost the same as the same period of the previous year of 26.8%.

In the most recent three-month period, from April to June (1Q), the operating profit margin rose from 22.3% in the same period last year to 25.6%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Jun, 2023	177	0	13	11	1.2	43.3	Aug 7, 2023	J-GAAP
Apr - Jun, 2024	229	51	56	51	5.5	87.5	Aug 8, 2024	J-GAAP
Apr - Jun, 2025	211	54	57	60	6.5	ー	Aug 8, 2025	J-GAAP
YoY	-7.9%	+5.9%	+1.8%	+17.6%	+18.7%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024	444	68	64	71	7.7	0	Nov 11, 2024	J-GAAP
Apr - Sep, 2025 Guidance	ー	ー	ー	ー	－	0	May 14, 2025	J-GAAP
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	816	104	125	186	20.1	0	May 14, 2024	J-GAAP
Mar, 2025	969	209	209	249	26.7	0	May 14, 2025	J-GAAP
Mar, 2026 Guidance	1,025	240	240	265	28.5	6	May 14, 2025	J-GAAP
YoY	+5.8%	+14.8%	+14.8%	+6.4%	+6.4%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Apr - Jun, 2024	229	51	56	51	5.5	22.3	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	215	17	8	20	2.2	7.9	Nov 11, 2024	J-GAAP
Oct - Dec, 2024	236	56	65	62	6.7	23.7	Feb 10, 2025	J-GAAP
Jan - Mar, 2025	289	85	80	116	12.5	29.4	May 14, 2025	J-GAAP
Apr - Jun, 2025	211	54	57	60	6.5	25.6	Aug 8, 2025	J-GAAP
YoY	-7.9%	+5.9%	+1.8%	+17.6%	+18.7%